AD	1		

Award Number: DAMD17-03-1-0277

TITLE: Chemotherapy Agents and the Inhibition of Neuronal Birthing in the Brain – The Cause of "Chemo Brain"

PRINCIPAL INVESTIGATOR: Robert A. Gross, M.D., Ph.D.

CONTRACTING ORGANIZATION: University of Rochester Rochester, NY 14642

REPORT DATE: November 2005

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

1. REPORT DATE 2. REPORT TYPE 3. DATES COVERED 1.01-11-2005 4. TITLE AND SUBTILE 5. COL 2004 – 1.4 Oct 2005 5. CONTRACT NUMBER 5. COL 2004 – 1.4 Oct 2005 5. CONTRACT NUMBER 5. COL 2004 – 1.4 Oct 2005 5. CONTRACT NUMBER 7. CALL TOWN TOWN TOWN TOWN TOWN TOWN TOWN TOWN			R FORM TO THE ABOVE ADD	RESS.		
4. TITLE AND SUBTITLE Chemotherapy Agents and the Inhibition of Neuronal Birthing in the Brain — The Cause of "Chemo Brain" 5b. GRANT NUMBER DAMD 17-03-1-0277 5c. PROGRAM ELEMENT NUMBER 6. AUTHOR(S) 6. AUTHOR(S) 5d. PROJECT NUMBER 5d. WORK UNIT NUMBER 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Rochester Rochester, NY 14642 9. SPONSORING I MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Material Command Fort Detrick, Maryland 217702-5012 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as "chemo brain." We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (S). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate sis a correlate sis a correlate sis is a correlate sis a correlate sis a correlate sis a correlate sis a correlate of heavioral declaine after chemotherapus we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in impro						
Chemotherapy Agents and the Inhibition of Neuronal Birthing in the Brain – The Cause of "Chemo Brain" 5b. GRANT NUMBER DAMD17-03-1-0277 5c. PROGRAM ELEMENT NUMBER 6. AUTHOR(S) 6. AUTHOR(S) 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Rochester Rochester, NY 14642 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 10. SPONSOR/MONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain.' We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain burrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central neurous system (S.). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of heavioral decline after chemotherapy. we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 16. SECURITY CLASSIFICATION OF: 19. TERMS DARMEN DARMEN DARMEN DARMEN DARMEN DARMEN			Annual			
Cause of "Chemo Brain" DAMD17-03-1-0277 S. PROGRAM ELEMENT NUMBER 6. AUTHOR(S) Robert A. Gross, M.D., Ph.D. 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Rochester Rochester, NY 14642 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release, Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain.' We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (S.O.) Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and the FLU) with agents that the continue. By testing with the will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of heavioral decline after chemotherapue we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 18. SUBJECT TERMS Breast Cancer 19. ABSTRACT Land ABSTRACT Land ABSTRACT Land ABSTRACT Land ABSTRACT S. PROGRAM ELEMENT NUMBER 19. NAME OF RESPONSIBLE PERSON. USAMEMOL 190. TELEMENT NUMBER (includes armore provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients.	4. TITLE AND SUBTIT	LE			5a. (CONTRACT NUMBER
Cause of "Chemo Brain" DAMDIT-703-1-0277 Sc. PROGRAM ELEMENT NUMBER 6. AUTHOR(S) Robert A. Gross, M.D., Ph.D. 5. WORK UNIT NUMBER 5. WORK UNIT NUMBER 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 10. SPONSOR/MONITOR'S ACRONYM(S) 11. SPONSOR/MONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain.' We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (S). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mile. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 18. SECURITY CLASSIFICATION OF: 19. TELEPHONE NUMBER (includes arms	Chemotherapy Ad	ents and the Inhibit	tion of Neuronal Birt	hing in the Brain – T	he 5b.	GRANT NUMBER
6. AUTHOR(S) Robert A. Gross, M.D., Ph.D. 5c. TASK NUMBER 5f. WORK UNIT NUMBER 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Rochester Rochester, NY 14642 8. PERFORMING ORGANIZATION REPORT NUMBER 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain'. We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hypocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition on heurogenesis is a correlate of behavioral decline after chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition on heurogenesis is a correlate of behavioral decline after chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow furthe				9	DA	MD17-03-1-0277
Robert A. Gross, M.D., Ph.D. 5e. TASK NUMBER 5f. WORK UNIT NUMBER 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Rochester Rochester, NY 14642 8. PERFORMING ORGANIZATION REPORT NUMBER 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSORIMONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as chemo brain.' We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain rier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is compare the effect of drugs that enter the CNS (cytoxa and 5-FLI) with agents that do not (Arost hat do not charge) and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS cytoxa and 5-FLI) with agents that do not (Arosta) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS cort reduce neurogenesis, we hope to develop an animal model of chemo brain' that will allow provided evidence that modification of chemotherapeutic regimens — specifically, using strategies to prevent CNS entry of drugs — would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TEMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER (include area					5c.	PROGRAM ELEMENT NUMBER
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Rochester Rochester, NY 14642 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain'. We hypothesize that the cognitive difficulties experienced by patients undergoing demotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is to compare the effect of drugs that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy, we will have provided evidence that modification of chemotherape must person and provided evidence that modification of chemotherape must person and provided evidence that modification of chemotherape must person and provided evidence that modification of chemotherape pust person and provided evidence that modification of chemotherape pust person and provided evidence that modification of chemotherape pust person and provided evidence that modification of chemotherape pust person and provided evidence that modification of chemotherape pust person and provided evidence that modification of chemotherape pust person and provided evidence that modification of chemotherape pust person and provided evidence that modification of chemotherape p	6. AUTHOR(S)				5d.	PROJECT NUMBER
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) U.S. ARMY Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain.' We hypothesize that the cognitive ediplicities experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapaty. We will have provided evidence that modification of chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy. We will have provided evidence that modification of chemotherapeutic genesis and the provided evidence that modification of chemotherapeutic enterior and the provided evidence that modification of chemotherapeutic enterior and the string strategies to prevent CNS entry of drugs – would be of great importance in improving the qua	Robert A. Gross, I	M.D., Ph.D.			5e. `	TASK NUMBER
University of Rochester Rochester, NY 14642 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain.' We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that on ont (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 17. INIMBER (Inimume) 18. NUMBER (Inimume) 19. NAME OF RESPONSIBLE PERSON USAMRMC 19. TELEPHONE NUMBER (Iniculae area					5f. V	WORK UNIT NUMBER
University of Rochester Rochester, NY 14642 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain.' We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that on ont (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 17. INIMBER (Inimume) 18. NUMBER (Inimume) 19. NAME OF RESPONSIBLE PERSON USAMRMC 19. TELEPHONE NUMBER (Iniculae area	7. PERFORMING ORG	SANIZATION NAME(S)	AND ADDRESS(ES)		8. P	ERFORMING ORGANIZATION REPORT
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain.' We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult my hether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherape, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 17. NUMBER 17. NUMBER 17. NUMBER (Include area						
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain.' We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 17. THIS PAGE 18. NUMBER 192. NAME OF RESPONSIBLE PERSON 19. TELEPHONE NUMBER (include erree	University of Roch	ester				
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain.' We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area	Rochester, NY 14	642				
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain.' We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area						
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain.' We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area						
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain.' We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area	9. SPONSORING / MO	NITORING AGENCY N	IAME(S) AND ADDRES	S(ES)	10.	SPONSOR/MONITOR'S ACRONYM(S)
11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain.' We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 17. THIS PAGE 18. NUMBER OF RESPONSIBLE PERSON USAMRMC 19. TELEPHONE NUMBER (include area				-()		· · · · · · · · · · · · · · · · · · ·
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain.' We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapey, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRMC	Fort Detrick, Mary	land 21702-5012				
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain.' We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherappy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area					11.	SPONSOR/MONITOR'S REPORT
13. SUPPLEMENTARY NOTES 14. ABSTRACT Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain.' We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area					1	NUMBER(S)
13. SUPPLEMENTARY NOTES 14. ABSTRACT Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain.' We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area						
13. SUPPLEMENTARY NOTES 14. ABSTRACT Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain.' We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area						
Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain.' We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area	Approved for Publ	ic Release; Distribu	ition Unlimited			
Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain.' We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area						
Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain.' We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area						
Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain.' We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area	13 SUPPLEMENTAR	Y NOTES				
Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain.' We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER OF RESPONSIBLE PERSON USAMRMC 19a. NAME OF RESPONSIBLE PERSON USAMRMC	13. GOLL ELIMENTAKT NOTES					
Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain.' We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER OF RESPONSIBLE PERSON USAMRMC 19a. NAME OF RESPONSIBLE PERSON USAMRMC						
Patients undergoing chemotherapy can experience a decline in cognitive abilities. While well described from a clinical perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain.' We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER OF RESPONSIBLE PERSON USAMRMC 19a. NAME OF RESPONSIBLE PERSON USAMRMC	14. ABSTRACT					
perspective, little is known of the neurological substrate for this difficulty, commonly known as 'chemo brain.' We hypothesize that the cognitive difficulties experienced by patients undergoing chemotherapy are the result of impaired neurogenesis, especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 179. NAME OF RESPONSIBLE PERSON USAMRMC 199. TELEPHONE NUMBER (include area)		ng chemotherapy ca	an experience a dec	line in cognitive abil	ities. While we	ell described from a clinical
especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area)					as 'chemo brain.' We hypothesize	
reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective is to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER OF PAGES USAMRMC 19b. TELEPHONE NUMBER (include area	that the cognitive	difficulties experiend	ced by patients unde	ergoing chemothera	py are the resi	ult of impaired neurogenesis,
to compare the effect of drugs that enter the CNS (Cytoxan and 5-FU) with agents that do not (Adriamycin and Taxol) with respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER OF PAGES USAMRMC 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area	especially in the hippocampus. We further hypothesize that agents that do not cross the blood-brain barrier will not show					
respect to their ability to impair the birthing of new neurons in the hippocampus of adult mice. By testing whether chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER OF PAGES USAMRMC 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area	reduced rates of neurogenesis, in contrast to agents that readily cross into the central nervous system (CNS). Our objective i					
chemotherapeutic agents that enter the CNS can reduce neurogenesis, we hope to develop an animal model of 'chemo brain' that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER OF PAGES USAMRMC 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area						
that will allow further studies. Furthermore, if we can show that inhibition of neurogenesis is a correlate of behavioral decline after chemotherapy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER OF RESPONSIBLE PERSON USAMRMC 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area						
after chemotherapy, we will have provided evidence that modification of chemotherapeutic regimens – specifically, using strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER OF RESPONSIBLE PERSON USAMRMC a. REPORT b. ABSTRACT c. THIS PAGE 19b. TELEPHONE NUMBER (include area						
strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients. 15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER OF RESPONSIBLE PERSON USAMRMC a. REPORT b. ABSTRACT c. THIS PAGE 19b. TELEPHONE NUMBER (include area						
15. SUBJECT TERMS Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER OF RESPONSIBLE PERSON USAMRMC USAMRMC 19b. TELEPHONE NUMBER (include area						
Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER OF RESPONSIBLE PERSON USAMRMC a. REPORT b. ABSTRACT c. THIS PAGE 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area	strategies to prevent CNS entry of drugs – would be of great importance in improving the quality of life in cancer patients.					
Breast Cancer 16. SECURITY CLASSIFICATION OF: 18. NUMBER OF RESPONSIBLE PERSON USAMRMC a. REPORT b. ABSTRACT c. THIS PAGE 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area						
16. SECURITY CLASSIFICATION OF: 18. NUMBER OF RESPONSIBLE PERSON USAMRMC a. REPORT b. ABSTRACT c. THIS PAGE 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area		1				
a. REPORT b. ABSTRACT c. THIS PAGE OF PAGES USAMRMC 19b. TELEPHONE NUMBER (include area	DIEGSI CATICEI					
a. REPORT b. ABSTRACT c. THIS PAGE 19b. TELEPHONE NUMBER (include area	16. SECURITY CLASS	SIFICATION OF:				
	a PEROPT	h ADSTDACT	a TUIC DACE		OF PAGES	
	1	1		1111	Ω	1
					U	

Table of Contents

Introduction	4
Body	4
Key Research Accomplishments	4
Reportable Outcomes	7
Conclusions	7
References	8
Appendices	

INTRODUCTION:

The purpose of the work was to test the hypothesis that chemotherapeutic agents can cause a reduction in neuronal birthing in the hippocampus. The rationale for this proposition is that the hippocampus is a crucial structure for memory function; as such, any disruption to its normal functioning – including disruption of the normal process of neuronal birthing – could lessen memory function. Such a process could underlie the condition popularly known as "chemo brain," in which persons who have received chemotherapy have reduced cognitive skills. To test this hypothesis, we chose chemotherapeutic agents of two groups, those that cross the bloodbrain barrier (cyclophosphamide, 5-FU) and those that do not (doxorubicin, paclitaxel); we predict, based on our hypothesis, that those that readily enter the brain would reduce neuronal birthing, whereas there would be no effect on birthing by those agents that do not enter the brain. A limitation to this series of controls is that detailed data regarding passage through the bloodbrain barrier are not available. Mice were to be treated with these agents, and bromo-deoxy-uridine (BrdU) would be injected, thereby labeling newly birthed cells. By use of immunohistochemical techniques, we sought to determine the number of birthed neurons and their destiny – for example, differentiation into neurons or glia.

REPORT:

Extenuating Circumstances:

The progress has been slow due to unforeseen circumstances. The original technician left unexpectedly (to enter an MD/PhD program), and it proved difficult to find another person with the requisite skill set. Training took several months. In addition, we were using the imaging facilities of a collaborator, who unexpectedly left this institution, leaving us temporarily without adequate microscopy support. The original pilot experiment, designed to test the safety and efficacy of the chosen chemotherapeutic regimens was finally completed, but with results that could not be interpreted with certainty (below). A second pilot was delayed until the proper technical support was in place. The second pilot and a definitive trial are now completed.

We have asked for and received a second twelve-month extension to continue this work.

Report:

1) We have completed three experiments.

Experiment #1: 4 mice per treatment group; 12 controls

- Doses of drug administered on days 1, 4 and 7:
 - o cyclophosphamide 50 mg/kg
 - o 5-FU 100 mg/kg or 60 mg/kg reduced because of ill health or death (75%) in higher dosage group
 - o Doxorubicin 5 mg/kg
 - o (no paclitaxel)
- BrdU administered on day 8, 4 injections q2hr 50 mg/kg
- Animals sacrificed 28 days after BrdU (to allow maturation)

Experiment #2: 5 mice per group, 10 controls

- Doses of drug administered on days 1, 4 and 7:
 - o 5-FU 60 mg/kg
 - o Paclitaxel 5 mg/kg
- BrdU administered as 4 injections q2hr on days 8-11 50 mg/kg
- Animals sacrificed 14 days after last BrdU injection

Experiment #3: 6 mice per group, 8 controls

- Doses of drug administered on days 1, 4 and 7:
 - o 5-FU 60 mg/kg
 - o Paclitaxel 5 mg/kg
 - o Cyclophosphamide 50 mg/kg
 - o Doxorubicin 5 mg/kg
- BrdU administered as 4 injections q2hr on day 8
- Animals sacrificed on day 9

We thus have experiments that allow us to assess maturation, with neuronal birthing in all cases occurring just after chemotherapy. Full maturation of birthed cells (experiment 3), partial maturation (experiment 2) and an immediate assessment of the birthing rate without maturation (experiment 1).

For all experiments, tissue was fixed *in vivo* and processed for chromagen staining with biotin-avidin. Chromagen staining was performed on every third hippocampal slice.

2) Results:

While this experiment suggested that the chemotherapeutic regimens chosen were relatively safe – in other words, that toxicity would not be a major confound – we still noted that weights declined slightly in the doxorubin- and 5-FU-treated mice, by 10-15% and 5%, respectively.


Experiments 1 and 2: After the definitive experiment (#3), it became evident that the results of these two experiments could not be used because the sectioning technique was insufficient to provide consistent cuts through the hippocampus. We have stored one hemisphere intact, however, and will go back and section the second hippocampus to provide data on maturation of newly birthed cells. One limitation, especially for the first experiment, is that exact numbers of cells may be difficult to determine: while a 28-day period after BrdU allows time for differentiation of newly-birthed cells to neuronal or glial types, it also reduces cell counts due to cell death.

Experiment 3:

This experiment measures the effect of chemotherapeutic agents on cell birthing in the hippocampus. Sacrifice of animals the day after BrdU administration allows for comparison to

Page 6 of 8

Experiment 1, which followed the same drug and BrdU schedules, but allowed for maturation of cells. In the Figure, a typical control and treated hippocampal slice are shown.



Condition	Cells / Slice	Cells / Hippocampus (% change from Control)	
	Mean ± SEM		
Controls	35 <u>+</u> 1	2103 <u>+</u> 56	
5-FU	30 <u>+</u> 1	1777 ± 57 (-16*)	
Cyclophosphamide	24 ± 0.8	1462 ± 51 (-30**)	
Paclitaxel	27 <u>+</u> 1	1632 ± 58 (-22**)	
Doxorubicin	23 <u>+</u> 1	1360 ± 68 (-35**)	

^{*} p < 0.002

3) Interpretation:

This experiment confirms our overall hypothesis, that chemotherapeutic agents may reduce cell birthing in the hippocampus, and may thus underlie the condition known as 'chemo brain.'

However, the design of the experiment was such that we included agents thought to cross the blood-brain barrier (5-FU, cyclophosphamide) and those thought not to cross (paclitaxel and

^{**} p < 0.001

doxorubicin). The experiment was designed so that there was an internal control consisting of agents that ought not to affect neuronal birthing. Data on chemotherapeutic agents crossing the blood-brain barrier are sparse, however, and we made assumptions based on human experience, as mice data were not definitive. Our result thus suggests either 1) that agents that penetrate the CNS poorly in humans may still penetrate sufficiently to affect hippocampal cell birthing; or 2) that the agents that penetrate the CNS poorly may have secondarily disrupted the blood-brain barrier, for example by affecting overall health. In this context it is worth noting that the drugs that affected health (as measured by weight) most, 5-FU and doxorubicin, had disparate effects on birthing, being the most and least suppressive.

Having worked out the technical details, and having shown a robust significant reduction of cell birthing resulting from all four chemotherapeutic regimens, a number of questions still remain unanswered. Experiment 3 shows that cell birthing is reduced, but does not speak to the eventual fate of those cells. To address this, we will section and stain tissue from Experiments 1 and 2, so as to determine the cell fates. If our previous results are a reliable guide (references), we expect that cell maturation will have begun by 2 weeks after labeling (Experiment 2) and that it will have nearly completed by 4 weeks (Experiment 4). Slices will be stained for BrdU and for the neuronal marker NeuN (and, if necessary, for the glial marker GFAP) and counted. The proportion of BrdU-positive cells that are neuronal, glial or neither will be tabulated and, for each chemotherapeutic regimen, compared to control. We expect to similar proportions of new cells evolving to neuronal or glial lineages, although it is possible that inhibition of cell birthing could skew the development toward a specific cell type.

To verify that mice treated with chemotherapeutic agents may serve as a model for chemo brain, behavioral measures should be correlated with cell counts. We hypothesize that animals with lower cell / neuronal counts will be poorer learners. At present, we are consulting with colleagues skilled in animal learning paradigms who will help plan appropriate experiments.

REPORTABLE OUTCOMES:

No publications or grant applications to date.

CONCLUSIONS:

Our results to date are sufficient to address our hypothesis, that chemotherapeutic agents may cause "chemo brain" because of an effect on cell birthing in the hippocampus. We have yet to complete the experiments that will determine newly-birthed cell differentiation and are exploring the possibility of behavioral experiments.

The hypothesis remains testable and important: if we can show an effect on neuronal birthing, a number of potential discoveries follow. Strategies that reduce penetration of chemotherapeutic agents into the CNS may allow adequate systemic treatment, but without the psychological-behavioral consequences.

REFERENCES:

Ferland, R.J., Gross, R.A. and Applegate, C.D. Increased mitotic activity in the dentate gyrus of the hippocampus of adult C57BL/6J mice exposed to the flurothyl kindling model of epileptogenesis. *Neuroscience* 115:669-683, 2002.

Ferland, R.J., Gross, R.A. and Applegate, C.D. Differences in hippocampal mitotic activity within the dorsal and ventral hippocampus following flurothyl seizures in mice. *Neuroscience Letters* 332:131-135, 2002.

Ferland, R.J., Williams, J.P., Gross, R.A. and Applegate, C.D. The effects of brain irradiation-induced decreases in hippocampal mitotic activity on flurothyl-induced epileptogenesis in adult C57BL/6J mice. *Experimental Neurology* 178:71-82, 2003.